Kewaunee Scientific releases transcript of 2026 annual shareholder meeting
KEQU•Debt reduction and segment performance
Long-term debt fell by about $20 million; NuAire seller notes were repaid; debt-to-equity improved to 0.61 from 0.99.
Lab Products Group sales increased 19.8% to $214.9 million; International segment sales rose 9.9% to $67.1 million.
Fiscal 2026 financial results and backlog
Revenue totaled $282 million for the year ended April 30, 2026; EBITDA rose to $22.4 million.
Order backlog was $165.9 million at April 30, 2026, down from $214.6 million, citing large international project completions.
Transcript released from virtual annual shareholder meeting
Kewaunee published a transcript from its virtual 2026 annual shareholder meeting attended by shareholders.
